

The Portfolio Companies of the Oulu Wellness Fund in October 2012

1. Ball-IT Oy

Ball-IT OY is a privately held Finnish company that was established in September 2005.

The company aims to become the leader in the development and production of real-time wireless sensing solutions. These solutions include enabling devices and modules as well as core software components for implementing consumer level User Interfaces.

The company is operating with a network of world-leading sensor and wireless technology vendors.

The company's management has on average more than 8 years experience from wireless industry and sensor technologies in commercial applications.

2. Juno Medical Oy

Tens of thousands of FAM assessments have proved that FAM shows, apart from the effect of physiotherapy treatment, also the effect of athletic training on the human neuromuscular system. That opens up totally new possibilities to optimize training. **FAM™ shows when an athlete's body does not respond to the training as planned - that helps to tackle arising problems earlier.**

FAM method provides a quick and non-invasive assessment result on the loading/recovery status of the body. The method is based on analyzing neuromuscular system with interferential current which is widely used in general physiotherapy. Assessment results help the athlete and the coach to make decision about training. Although there is plenty of training related material available, each athlete responds individually on exercises. **With the help of FAM™ method, the athlete receives individualized, immediate information on his/hers own body.**

A new FAM-device is now Check! Later more.

3. Pixolane Oy

Action Game for PlayStation " Vehicle arcade genre"

4. ProWellness Oy

Chronic diseases are an ever existent, rapidly-growing problem that is the leading cause of mortality and premature deaths in the world. This group of diseases currently represents 60 % of all deaths globally with almost half of the deceased less than 70 years of age. Accordingly to the WHO, cardiovascular diseases are responsible for 30 % of deaths worldwide, making them the leading cause of death globally. In other categories, there are an estimated 170 million cases of diabetes and 210 million cases of COPD in the world today. While diabetes deaths are predicted to increase by more than 50 % within ten years unless urgent action is taken, COPD is expected to become the world's third largest cause of death by 2030.

ProWellness has been developing solutions for the prevention, management, and care of chronic diseases in co-operation with healthcare professionals since 1996. ProWellness delivers clinical systems that improve the quality of care through structured collection and region wide sharing of information that allows for the creation of clinical, managerial, and statistical reports. Our objective is to achieve a traceable and reportable care pathway that would help healthcare professionals and administrators better manage increasing amounts of information and workload.

5. Sensinode Oy

Sensinode is a technology leader for the Internet of Things, offering the latest open standard IP and Web technology optimized for constrained devices and networks. Sensinode is actively developing and promoting open standards at the IETF, ZigBee, ETSI and the IPSO Alliance. In a nutshell, this technology makes the Internet of Things possible by greatly reducing the complexity and overhead of key Internet and Web protocols.

6. Genecodebook Oy

Analysoi geeniperimästäsi saatavaa tietoa ainutlaatuisen tarkasti, helposti ja luotettavasti. Testaamalla ja tuloksia tulkitsemalla voidaan luotettavasti selvittää yksilöllisiä terveystarpeita ja muita henkilökohtaisia ominaisuuksia.

7. Biosilta Oy

BioSilta is a rapidly expanding biotech company, which specializes in microbial cell culture technology, and provides the patented EnBase technology to research laboratories. EnBase technology is the world's first

complete microbial cultivation kit for the production of up to 20 times more bacteria and 10 times more recombinant protein than traditional laboratory media.

Simply explained, our technology provides an optimal environment for microorganisms to ensure a bigger and better harvest of cells compared to standard shaken cultures. Our mineral salt medium includes a composition of trace elements and enzymatic controlled-release of glucose, mimicking the fed batch process. EnBase can be utilized in volumes from 0.15 mL in 96 well plates to litre's in single-use or traditional bioreactors. EnBase currently is found in a tablet and liquid format. EnBase provides researchers more time for research and beneficial cost-savings.

8. BBS = Biactive Bone Substitutes Oy

Bioactive Bone Substitutes Ltd. (BBS) is a biomedical technology company developing innovative, biologically active medical device implants to be used in orthopedic surgery.

Our first product, ARTEBONE, is made from a natural animal source of bone material that has a superior capability of bone regeneration compared to existing products.

While the company's initial target is orthopedics, there are significant growth opportunities for this innovative biomaterial.

Bioactive Bone Substitutes-BBS Ltd. has developed a novel bioactive natural bone product derived from reindeer - ARTEBONE®. Reindeers are the product of Mother Nature's experiment in optimizing biology for the rapid regeneration of bone. Reindeer discard and grow new antler bone at a rate that is the equivalent to replacing thirty percent (30%) of their total body weight each and every year during their lifespan. In early pioneering research studies conducted by BBS scientists, extracts made from reindeer bone were compared to similar extracts made from a variety of other animals (sheep, cow, pig, etc.). The bioactivity in the reindeer extract, as measured in an ectopic bone-forming animal model, greatly exceeded (up to 10X) the bioactivity of all the other animal extracts tested.
